5 of Last Week's Biggest Losers

There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers.

Company

Nov. 1

Weekly Loss

Amarin  (NASDAQ: AMRN  )

$1.64

25%

Hutchinson  (NASDAQ: HTCH  )

$3.03

23%

Ellie Mae  (NYSE: ELLI  )

$24.03

21%

Eagle Rock Energy Partners  (NASDAQ: EROC  )

$6.16

16%

Teva Pharmaceuticals  (NYSE: TEVA  )

$37.12

11%

Source: Barron's.

Let's start with Amarin. The former high-flying biotech continues its dramatic fade in 2013. The stock has shed nearly 80% of its value this year, and it's now trading at its lowest level in more than three years. This week's 25% blow came after the Food and Drug Administration announced that its triglyceride-reducing drug Vascepa may not merit approval in lowering the cardiovascular problems in select patients. It also didn't help that FBR Capital initiated coverage on Amarin with a ho-hum "market perform" rating and a price target that was below where it was trading at the time. Amarin did close out the week below FBR's $2 price target.

Hutchinson's drop came largely on Friday, after it posted an adjusted loss of $0.40 a share on flat revenue growth. Analysts were expecting only $0.24 a share in red ink, making this the second consecutive quarter where Hutchinson delivers a much larger deficit than Wall Street was forecasting. The future won't get a whole lot better. Hutchinson sees suspension assemblies for the new quarter clocking in essentially flat sequentially.

Ellie Mae investors were in dismay after the mortgage-processing solutions provider posted disappointing financial results. Ellie Mae was smacked down by a drop in mortgage origination volume. It tried to overcome the sloppy results with the acquisition of MortgageCEO -- a provider of CRM and marketing solutions -- but investors still chose to cash out given the decaying fundamentals of the mortgage industry in general.

Eagle Rock Energy Partners became the latest master limited partnership to slash its yield, announcing that it would pay just $0.15 per unit this quarter. It has previously shelled out $0.22 per unit. Given the partnership's leveraged balance sheet and its soft earnings that made the higher payout rate unsustainable, some market watchers saw this coming, but too many investors were spoiled by high yield without considering the likely reduction.

Teva slipped after its CEO was let go. The Israeli-based drug company also served up uninspiring quarterly results. Revenue inched 2% higher, but earnings moved in the other direction. It also didn't help that the CEO's departure wasn't entirely clear. Teva's official announcement was that he stepped down, but he told a reporter it wasn't his decision to resign. It can't help that Teva is expanding its bribery investigation into Eastern Europe, casting even more clouds over the pharmaceuticals giant.

Ready for a bounce
If you owned some of these losers, how about following the smart money into winners? If you're looking for some long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2710766, ~/Articles/ArticleHandler.aspx, 10/2/2014 9:01:28 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement